125 related articles for article (PubMed ID: 31152642)
1. Remission of Late-Onset Post-Liver Transplantation Non-Hodgkin Lymphoma.
Stardelova KG; Stojanovik A; Jovanovska RP; Stavrik S; Dimitrova M; Kostova NM; Serafimoski V
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2019 May; 40(1):67-71. PubMed ID: 31152642
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
[TBL] [Abstract][Full Text] [Related]
3. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
4. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
Mamzer-Bruneel MF; Lomé C; Morelon E; Levy V; Bourquelot P; Jacobs F; Gessain A; Mac Intyre E; Brousse N; Kreis H; Hermine O
J Clin Oncol; 2000 Nov; 18(21):3622-32. PubMed ID: 11054435
[TBL] [Abstract][Full Text] [Related]
5. Combined radiation and chemotherapy in posttransplant lymphoproliferative disorder.
Tsai DE; Stadtmauer EA; Canaday DJ; Vaughn DJ
Med Oncol; 1998 Dec; 15(4):279-81. PubMed ID: 9951693
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
7. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
8. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
9. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
10. Posttransplant lymphoma--a single-center experience of 500 liver transplantations.
Norin S; Kimby E; Ericzon BG; Christensson B; Sander B; Söderdahl G; Hägglund H
Med Oncol; 2004; 21(3):273-84. PubMed ID: 15456956
[TBL] [Abstract][Full Text] [Related]
11. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
13. [Lymphoproliferative disease following kidney transplantation].
Merkle M; Rupprecht HD
Dtsch Med Wochenschr; 2005 Jul; 130(28-29):1691-4. PubMed ID: 16003604
[TBL] [Abstract][Full Text] [Related]
14. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
[TBL] [Abstract][Full Text] [Related]
16. A case of intravascular lymphoma diagnosed in an explanted liver after liver transplantation.
Kuramitsu K; Fukumoto T; Yano Y; Hirano H; Misumi T; Katayama Y; Kawano H; Yakushijin K; Zen Y; Itoh T; Ku Y
Transpl Int; 2015 Oct; 28(10):1245-50. PubMed ID: 26010984
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
Tobinai K; Ogura M; Itoh K; Kinoshita T; Hotta T; Watanabe T; Morishima Y; Igarashi T; Terauchi T; Ohashi Y;
Cancer Sci; 2010 Dec; 101(12):2579-85. PubMed ID: 20942866
[TBL] [Abstract][Full Text] [Related]
18. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Alliot C
J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
[No Abstract] [Full Text] [Related]
19. A meta-analysis on Rituximab combined CHOP chemotherapy for non-Hodgkin lymphoma in China.
Hou S; Yang W
Saudi Med J; 2011 Jul; 32(7):675-8. PubMed ID: 21748202
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
Short NJ; Kantarjian HM; Ko H; Khoury JD; Ravandi F; Thomas DA; Garcia-Manero G; Khouri M; Cortes JE; Wierda WG; Verstovsek S; Estrov Z; Ferrajoli A; Thompson PA; Pierce S; O'Brien SM; Jabbour E
Am J Hematol; 2017 Jun; 92(6):E114-E117. PubMed ID: 28295472
[No Abstract] [Full Text] [Related]
[Next] [New Search]
